National Heart, Lung, And Blood Institute (nhlbi)
Clinical trials sponsored by National Heart, Lung, And Blood Institute (nhlbi), explained in plain language.
-
New heart procedure aims to zap stubborn arrhythmias
Disease control ENROLLING_BY_INVITATIONThis early study tests a new catheter technique called VINTAGE for people with ventricular arrhythmia that hasn't improved with standard treatment. The procedure uses special catheters to reach and destroy heart tissue causing the abnormal rhythm. Thirty adults will be enrolled a…
Phase: NA • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Heart lasso: new catheter belt tightens leaky valve without surgery
Disease control TerminatedThis early study tests a new procedure called TRAIPTA for people with severe tricuspid valve regurgitation, a condition where a heart valve leaks and causes breathlessness and fluid buildup. The procedure uses a catheter to place a belt-like device around the heart from inside, t…
Phase: NA • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for rare bone marrow diseases: drug tames immune attack
Disease control OngoingThis study tests a pill called ruxolitinib for people whose immune system attacks their bone marrow, causing conditions like severe anemia. The drug aims to stop this attack and help the bone marrow recover. Participants take the pill twice daily for up to 6 months and are follow…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Sickle cell drug mitapivat faces Long-Term safety check in small study
Disease control OngoingThis study looks at the long-term safety and tolerability of the drug mitapivat in adults with stable sickle cell disease. Participants, who previously benefited from mitapivat in an earlier study, take the drug twice daily for up to 48 weeks, with an option to continue for anoth…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take on kidney cancer in early trial
Disease control OngoingThis early-phase study tests a new gene therapy for people with advanced clear cell kidney cancer. Doctors take a patient's own white blood cells, modify them in the lab to better attack cancer, and return them to the body. The main goals are to check safety and see if tumors shr…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New hope for older leukemia patients: targeted pill shows promise
Disease control OngoingThis phase II study tests a daily pill called PCI-32765 (ibrutinib) in 86 people with chronic lymphocytic leukemia or small lymphocytic lymphoma who are over 65 or have a specific genetic change (17p deletion). These groups often do not respond well to standard chemotherapy. Part…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug combo aims to make stem cell transplants safer for sickle cell patients
Disease control OngoingThis early-phase trial tests a new combination of drugs (briquilimab, abatacept, and alemtuzumab) plus low-dose radiation to prepare people with sickle cell disease for a stem cell transplant from a half-matched family donor. The goal is to reduce serious side effects like graft-…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New stem cell transplant could help sickle cell patients without a perfect donor match
Disease control OngoingThis study tests a stem cell transplant using cells from a half-matched family donor, combined with low-dose radiation and drugs to prevent rejection, for adults with severe sickle cell disease or beta-thalassemia. The goal is to see if this gentler approach can replace the disea…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Half-Matched stem cell transplant shows promise for sickle cell disease
Disease control OngoingThis study tests a stem cell transplant from a half-matched relative (haploidentical donor) for adults with severe sickle cell disease. The goal is to see if a gentler conditioning regimen can reduce complications like graft rejection and graft-versus-host disease. Participants r…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New combo aims to boost remission in leukemia
Disease control OngoingThis pilot phase 2 study tests a combination of ibrutinib (taken daily) and a short course of fludarabine (given in cycles 3 and 4) in 29 patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see how many patients achieve a …
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug combo shows promise for rare blood disorder
Disease control OngoingThis study tests whether adding eltrombopag to standard immunosuppressive therapy can improve blood cell counts in people with untreated severe aplastic anemia. Participants receive horse-ATG and cyclosporine plus eltrombopag for up to 6 months. The goal is to see if this combina…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New antibody could boost stem cell transplant success for blood disorders
Disease control OngoingThis study tests whether adding an antibody called briquilimab (JSP191) to a standard stem cell transplant can help more donor cells take root in people with sickle cell disease or beta-thalassemia. About 40 patients aged 13 and older will receive the antibody along with low-dose…
Phase: PHASE1, PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug may keep aplastic anemia from returning
Disease control OngoingThis study tests whether the drug sirolimus can prevent severe aplastic anemia from coming back after patients stop taking cyclosporine. About 84 people aged 2 and older who have responded to initial treatment will be randomly assigned to either take sirolimus for 3 months or jus…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Study withdrawn: extended access to fostamatinib for transplant patients never launched
Disease control TerminatedThis study was designed to give people who had a stem cell transplant and developed low blood cell counts (anemia, low platelets) continued access to the drug fostamatinib. Only those who responded well in a prior study were eligible. The goal was to see if they could maintain st…
Phase: PHASE2 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New heart signal recorder aims to sharpen procedure accuracy
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests a new device called the EDEN system that records and classifies electrical signals from the heart during medical procedures. About 50 adults having heart procedures for ventricular arrhythmia or pacing will participate. The device works alongside standard equipme…
Phase: NA • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 01:00 UTC
-
2000 heart failure patients enrolled in landmark phenotyping study
Knowledge-focused ENROLLING_BY_INVITATIONThis study will collect blood, urine, stool, and DNA samples from 2000 adults with heart failure to better understand how the disease progresses. Researchers will analyze proteins and other factors linked to declining heart function. Participants will be followed for up to 5 year…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 01:00 UTC
-
Tiny study probes Mitapivat's inner workings in sickle cell
Knowledge-focused OngoingThis observational study will examine how the drug mitapivat changes red blood cells in 6 people with sickle cell disease. Researchers will measure oxygen binding and cell survival markers from blood samples and muscle oxygen tests. The goal is to understand the drug's effects, n…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 01:00 UTC
-
Blood samples sought to unlock secrets of sickle cell disease
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood and other samples from people with sickle cell disease and healthy volunteers to help researchers understand how inflammation affects blood vessels. Up to 2,000 adults aged 18 and older will take part. The samples will be used in lab tests to support fut…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
NIH opens screening study to find candidates for blood disorder research
Knowledge-focused ENROLLING_BY_INVITATIONThis study screens up to 10,000 people with blood disorders or healthy volunteers to see if they can safely join other active research studies at the National Heart, Lung, and Blood Institute. Participants undergo clinical, imaging, and lab tests. If no suitable study is availabl…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Massive data collection aims to spark breakthroughs in blood disorders
Knowledge-focused ENROLLING_BY_INVITATIONThis study gathers medical information from up to 10,000 people with blood or heart conditions, as well as stem cell donors, treated at the National Institutes of Health. Researchers will review participants' medical records, test results, and treatments to build a database for g…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Scientists dive deep into Epcoritamab's effects on Hard-to-Treat blood cancers
Knowledge-focused OngoingThis study looks at blood, lymph node, and bone marrow samples from 5 people with chronic lymphocytic leukemia or Richter syndrome who are receiving the drug epcoritamab. Researchers want to understand how the drug changes immune cells and tumor cells over time. The goal is to le…
Phase: PHASE1 • Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Decades-Long heart study reveals how young adult habits shape future risk
Knowledge-focused OngoingThis study follows over 5,000 Black and White men and women from age 18-30 for many years to see how their lifestyles and health habits affect their risk of heart disease later in life. Researchers measure things like blood pressure, weight, and cholesterol to understand why some…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Massive study tracks 5,888 seniors to uncover heart disease triggers
Knowledge-focused OngoingThis study followed nearly 6,000 adults aged 65 and older to learn what factors predict heart disease, stroke, and related health problems. Researchers aimed to identify risks and understand what leads to disability or death after a heart event. The study did not test a new treat…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Heart disease mystery: 6,800 diverse adults tracked for decades
Knowledge-focused OngoingThis study followed over 6,800 adults from different racial and ethnic backgrounds to understand how heart disease develops over time. Participants were healthy at the start and were monitored for risk factors and heart-related events like heart attacks and strokes. The goal is t…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Scientists unravel genetic secrets of bone marrow failure
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to understand the genetic and molecular changes in people with bone marrow failure disorders. Researchers will analyze blood and bone marrow samples from up to 1,400 participants to track how these changes evolve over time. The goal is to better predict disease ou…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC